PMC:7574920 / 4131-4551 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T15","span":{"begin":78,"end":84},"obj":"Body_part"},{"id":"T16","span":{"begin":290,"end":293},"obj":"Body_part"},{"id":"T17","span":{"begin":379,"end":382},"obj":"Body_part"}],"attributes":[{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"An active SARS-CoV-2 infection can be diagnosed by detecting either the viral genome or viral antigens in appropriate human samples. Assays for detecting SARS-CoV-2 antigens are limited by the sensitivity, specificity, and production speed of diagnostic antibodies, whereas detecting viral RNA only requires specific oligonucleotides. Therefore, an assay that detects SARS-CoV-2 RNA facilitates testing of large cohorts."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T30","span":{"begin":10,"end":18},"obj":"Disease"},{"id":"T31","span":{"begin":21,"end":30},"obj":"Disease"},{"id":"T32","span":{"begin":154,"end":162},"obj":"Disease"},{"id":"T33","span":{"begin":368,"end":376},"obj":"Disease"}],"attributes":[{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"An active SARS-CoV-2 infection can be diagnosed by detecting either the viral genome or viral antigens in appropriate human samples. Assays for detecting SARS-CoV-2 antigens are limited by the sensitivity, specificity, and production speed of diagnostic antibodies, whereas detecting viral RNA only requires specific oligonucleotides. Therefore, an assay that detects SARS-CoV-2 RNA facilitates testing of large cohorts."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T47","span":{"begin":3,"end":9},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T48","span":{"begin":118,"end":123},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T49","span":{"begin":395,"end":402},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"An active SARS-CoV-2 infection can be diagnosed by detecting either the viral genome or viral antigens in appropriate human samples. Assays for detecting SARS-CoV-2 antigens are limited by the sensitivity, specificity, and production speed of diagnostic antibodies, whereas detecting viral RNA only requires specific oligonucleotides. Therefore, an assay that detects SARS-CoV-2 RNA facilitates testing of large cohorts."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T2","span":{"begin":94,"end":102},"obj":"Chemical"},{"id":"T3","span":{"begin":165,"end":173},"obj":"Chemical"},{"id":"T4","span":{"begin":317,"end":333},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_7754"}],"text":"An active SARS-CoV-2 infection can be diagnosed by detecting either the viral genome or viral antigens in appropriate human samples. Assays for detecting SARS-CoV-2 antigens are limited by the sensitivity, specificity, and production speed of diagnostic antibodies, whereas detecting viral RNA only requires specific oligonucleotides. Therefore, an assay that detects SARS-CoV-2 RNA facilitates testing of large cohorts."}

{"project":"LitCovid-PubTator","denotations":[{"id":"79","span":{"begin":118,"end":123},"obj":"Species"},{"id":"80","span":{"begin":368,"end":378},"obj":"Species"},{"id":"81","span":{"begin":154,"end":164},"obj":"Species"},{"id":"82","span":{"begin":317,"end":333},"obj":"Chemical"},{"id":"83","span":{"begin":10,"end":30},"obj":"Disease"}],"attributes":[{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"Tax:9606"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"Tax:2697049"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:2697049"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"MESH:D009841"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"An active SARS-CoV-2 infection can be diagnosed by detecting either the viral genome or viral antigens in appropriate human samples. Assays for detecting SARS-CoV-2 antigens are limited by the sensitivity, specificity, and production speed of diagnostic antibodies, whereas detecting viral RNA only requires specific oligonucleotides. Therefore, an assay that detects SARS-CoV-2 RNA facilitates testing of large cohorts."}

{"project":"LitCovid-sentences","denotations":[{"id":"T29","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T30","span":{"begin":133,"end":334},"obj":"Sentence"},{"id":"T31","span":{"begin":335,"end":420},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"An active SARS-CoV-2 infection can be diagnosed by detecting either the viral genome or viral antigens in appropriate human samples. Assays for detecting SARS-CoV-2 antigens are limited by the sensitivity, specificity, and production speed of diagnostic antibodies, whereas detecting viral RNA only requires specific oligonucleotides. Therefore, an assay that detects SARS-CoV-2 RNA facilitates testing of large cohorts."}